Vivo Bio Tech Limited reported a net loss of ₹170.88 lakh for the financial year ended March 31, 2026, a notable shift from the previous year’s profit. This occurred despite a modest revenue growth of 3.0% to ₹5,377.55 lakh. The company incurred significant capital expenditure of ₹37.44 crore, primarily for a new large-animal facility and analytical instrumentation, impacting its liquidity and debt-service ratios.
Vivo Bio Tech Reports FY26 Financials
Vivo Bio Tech Limited has announced its financial results for the fiscal year ended March 31, 2026. The company reported a net loss of ₹170.88 lakh on a consolidated basis, contrasting with a profit of ₹728.26 lakh in the previous fiscal year. This downturn was accompanied by a revenue increase of 3.0% to ₹5,377.55 lakh.
Capital Expenditure and Liquidity
A significant factor influencing the company’s financial performance was substantial capital deployment, amounting to ₹37.44 crore, marking a 68% year-over-year increase. These investments were directed towards a new NGCMA GLP-certified large-animal facility, advanced analytical instrumentation, and continued portfolio expansion. The company’s liquidity position weakened, with the current ratio decreasing to 0.94x from 1.56x in the prior year.
Key Financial Ratios and Performance
The company’s profitability metrics saw a decline, with the Net Profit Margin from operations turning negative at (4.52)%. Return on Equity also swung negative to (2.26)%. The Standalone Statement of Profit and Loss shows a loss after tax of ₹193.61 lakh for FY 2025-26. Despite the overall net loss, the company’s inventory turnover and trade receivables turnover ratios showed improvement.
Segment Performance
The Dog (large-animal) studies segment was identified as an outperformer, directly benefiting from GLP certification for the canine facility. Conversely, Bioanalytical services and Analytical Chemistry underperformed despite significant equipment investment, indicating challenges in capacity utilization and revenue conversion.
Source: BSE
